ReviewTherapeutics and clinical risk management2019
Fosfomycin: the characteristics, activity, and use in critical care.
Review in Therapeutics and clinical risk management, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Epidemiology of clinical antimicrobial-resistant Enterobacterales in Togo over three decades: a systematic review and meta-analysis, with recommendations and alternative solutions.BMC infectious diseases · 2025Pooled it
- Giving Antibiotics a Second Chance: Evolutionary Trade-Offs and Phage-Driven Restoration of Antibiotic Susceptibility.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Fosfomycin Resistance: An Update on the Anthropogenic Impact Through Agriculture.Pathogens (Basel, Switzerland) · 2025Review
- Fosfomycin in Complicated Intra-Abdominal Infections in an Intensive Care Setting: Does It Improve the Outcome? A Retrospective Observational Study.Antibiotics (Basel, Switzerland) · 2025Article
- Efficacy and Safety of Fosfomycin Disodium in Patients with Bacterial Infections: A Single-Center, Real-Life Clinical Study.Journal of clinical medicine · 2025Article
- Monitoring Plasma Concentrations of Intravenously Administered Fosfomycin to Prevent Drug-Related Adverse Events: A Retrospective Observational Study.Antibiotics (Basel, Switzerland) · 2025Article
- Intravenous Fosfomycin for Difficult-to-Treat Infections: A Real-Life Multicentric Study in Italy.Antibiotics (Basel, Switzerland) · 2025Article
- Antibiotics and Opportunities of Their Alternatives in Pig Production: Mechanisms Through Modulating Intestinal Microbiota on Intestinal Health and Growth.Antibiotics (Basel, Switzerland) · 2025Review
- Salmonella isolated from street foods and environment of an urban park: A whole genome sequencing approach.PloS one · 2025Article
- Antibiotics with antibiofilm activity - rifampicin and beyond.Frontiers in microbiology · 2024Review
- UropathogenicMicroorganisms · 2023Review
- Antimicrobial Peptides Demonstrate Activity against Resistant Bacterial Pathogens.Infectious disease reports · 2023Review
- Clinical Use of Intravenous Fosfomycin in Critical Care Patients in Taiwan.Pathogens (Basel, Switzerland) · 2023Article
- Developmental Pharmacokinetics of Antibiotics Used in Neonatal ICU: Focus on Preterm Infants.Biomedicines · 2023Review
- Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations.Antibiotics (Basel, Switzerland) · 2022Article
- Prescription Pattern of Intravenous Fosfomycin in a Provincial Hospital in Thailand.Infection & chemotherapy · 2022Article
- A Real-world Study on Prescription Pattern of Fosfomycin in Critical Care Patients.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2021Article
- Synergistic Antibacterial Effects of Meropenem in Combination with Aminoglycosides against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Article
- Fosfomycin, Applying Known Methods and Remedies to A New Era.Diseases (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fosfomycin (C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.